Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening

Launched by CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL · Jul 25, 2024

Keywords

ClinConnect Summary

The INDIGO study is a clinical trial aimed at improving how many women participate in cervical cancer screening in France. Cervical cancer is a significant health issue, with around 3,000 new cases reported each year. The national screening program, called DOCCU, invites women aged 25 to 65 to get screened, but only 59% of those invited actually participate. This trial will explore whether having general practitioners (family doctors) encourage women to get screened can make a difference in participation rates.

To be part of this study, women need to be between the ages of 25 and 65, live in the Ile-De-France region, and be eligible for the DOCCU program. This means they should not have had a hysterectomy and should not be receiving treatment for cervical cancer or pre-cancerous conditions. If eligible, participants can expect to work with their general practitioners, who will provide support and information about the screening process. The study is not yet recruiting participants, but it aims to find effective ways to increase awareness and participation in cervical cancer screening, ultimately helping to catch potential issues earlier and improve women's health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Woman aged 25 to 65 living in Ile-De-France
• • Eligible for DOCCU (not hysterectomized, not followed for a pre-cancerous or cancerous lesion of the cervix)
• • Having declared the investigating general practitioner as a treating physician (MT) and whose MT practices in the territory of a CPTS in the UPEC area
• • Affiliate to a social security scheme or beneficiary of such a scheme
• Exclusion Criteria:
• • Patient already included in a study on DOCCU
• • Patient excluded from organized screening (cervical cancer, hysterectomy).
• • Patient's opposition to participating in the study